
EQUAL Scedosporiosis/Lomentosporiosis Score 2021: An ECMM Score Derived From Current Guidelines to Measure QUALity of the Clinical Management of Scedosporiosis/Lomentosporiosis

Jannik Stemler^{1,2,3}, Michaela Lackner⁴, Sharon Chen⁵, Martin Hoenigl^{6,7,8}, Oliver A. Cornely^{1,2,3}

"University of Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany; "University of Cologne, Chair Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (ECAD), Cologne, Germany; "University of Cologne, Clinical Trials Centre Cologne (Zif Sidh), Cologne, Germany; "Department of Hygiene, Medical Microbiology and Public Health, Medical University in Instruct, Instruct, a Clinical Pathology and Medical Research, Westmead Hospital and the University of Sydney, Sydney, Australia; "Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, USA; "Division of Infectious Diseases, Medical University of California San Diego, San Diego, USA; "Division of Infectious Diseases, Medical University of Care, Austria."



DOI: 10.4126/FRL01-006399228 November 2021

Background

The EQUAL Scedosporiosis/Lomentosporiosis Score weights and aggregates factors for ideal management of scedosporiosis and lomentosporiosis. Scores reflect the strongest guideline recommendations. EQUAL Score Cards are a quick reference to quantify guideline adherence and to support antifungal stewardship.

Maximum Score		
	Scedosporiosis	Lomentosporiosis
Diagnosis	18	
Treatment	9	
If voriconazole is not used		
First Line Treatment	3	
Second Line Treatment / first line not available	1	2
Follow-up	4	
Total	341	342

Comment

- 1 reduces to 29 points, if voriconazole is not used as first-line treatment
- reduces to 30 or 29 points, respectively, if voriconazole is used as monotherapy in first-line treatment or if other antifungals are used

References

Stemler et al. J Antimicrob Chemother 2021 Hoenigl et al. The Lancet Infect Dis 2021 Shoham et al. Clin Transplant 2019 Blyth et al. Intern Med J 2014 Tortorano et al. Clin Microbiol Infect 2014













- Imaging incl. CNS to document the extent of disease
 - ID and/or mycological reference laboratory consultation

Infected tissue(s) or body fluids:

- Culture from BAL or any other tissue/fluid² (morphology, physiology)
- Direct microscopic examination with calcofluor white staining
 Blood cultures (to rule out hematogenous dissemination)
- Species complex/species identification (morphology, ITS-1/2)
- Further molecular and/or proteomic analysis of clinical specimens
 - or cultures (MALDI-TOF, ß-tubulin sequencing, pan-fungal PCRs)

3

2 1 1

3

3

3

-1

3

- Histopathological examination of biopsy (Grocott's/PAS stain)
- Antifungal susceptibility testing
- Immediate treatment initiation
- Surgical debridement of suspected infected sites (if possible)

Scedosporium (apiospermum):

- Voriconazole-based therapeutic regimen (d1: 2x 6mg/kg/d; from d2: 2x 4mg/kg/d)
- Isavuconazole or posaconazole based treatments
- Amphotericin B (liposomal or lipid complex) monotherapy

Lomentospora (prolificans):

- Voriconazole + terbinafine 500-1000 mg/d ± other antifungals
- Voriconazole monotherapy
- Isavuconazole or posaconazole in combination with other antifungals
- Amphotericin B (liposomal or lipid complex) monotherapy
- Therapeutic drug monitoring for voriconazole
- Weekly response assessment via imaging of infected body site
 - Consider reducing immunosuppression

Consider mould active antifungal prophylaxis in patients with neutropenia >10d or allo HSCT and recipients of donor lungs colonized with Scedosporium spp. or Lomentospora spp.

Respiratory samples from CF patients: SceSel+ medium, incubation time min. 7 days up to 14 days.